Patients with a L8585R-positive tumor had a significantly better mPFS (12.6 vs. 6.3 months, P = 0.03) and a trend of a longer mOS (28.9 vs. 25.6 months) if EGFR-TKI was the first-line rather than the later-line treatment. Here, EGFR is linked to neoplasm.